Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 227

1.

Increasing Syphilis in Rhode Island: Return of an Old Foe.

Junco-Fernández A, Montgomery MC, Crowley C, Bertrand T, Marak TP, Maynard MA, Gummo C, Flanigan TP, Chan PA.

R I Med J (2013). 2019 Feb 1;102(1):50-54.

PMID:
30709076
2.

A Nearly 50% Decrease in New HIV Diagnoses in Rhode Island from 2006-2016: Implications for Policy Development and Prevention.

Chan PA, Montgomery M, Marak T, Bertrand T, Flanigan TP, Fernández AJ, Alexander-Scott N, Garland JM, Nunn AS.

R I Med J (2013). 2018 Oct 1;101(8):41-45.

3.

First confirmed case of Powassan neuroinvasive disease in Rhode Island.

Patel KM, Johnson J, Zacharioudakis IM, Boxerman JL, Flanigan TP, Reece RM.

IDCases. 2018 Mar 23;12:84-87. doi: 10.1016/j.idcr.2018.03.016. eCollection 2018.

4.

Clinical Benefits and Cost-Effectiveness of Laboratory Monitoring Strategies to Guide Antiretroviral Treatment Switching in India.

Freedberg KA, Kumarasamy N, Borre ED, Ross EL, Mayer KH, Losina E, Swaminathan S, Flanigan TP, Walensky RP.

AIDS Res Hum Retroviruses. 2018 Jun;34(6):486-497. doi: 10.1089/AID.2017.0258. Epub 2018 May 3.

5.

Assessing acceptability and feasibility of provider-initiated HIV testing and counseling in Ghana.

Tabb Z, Moriarty K, Schrier MW, Amekah E, Flanigan TP, Lartey M.

R I Med J (2013). 2017 Aug 1;100(8):19-22.

PMID:
28759895
6.

Effective HIV Prevention Interventions and the Need for Rapid Mobilization to Address HIV Outbreaks Among At-Risk Populations.

Chan PA, Flanigan TP.

J Infect Dis. 2017 May 15;215(10):1491-1492. doi: 10.1093/infdis/jix101. No abstract available.

7.

Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine.

Aibana O, Bachmaha M, Krasiuk V, Rybak N, Flanigan TP, Petrenko V, Murray MB.

BMC Infect Dis. 2017 Feb 7;17(1):129. doi: 10.1186/s12879-017-2230-2.

8.

Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy.

Singini I, Campbell TB, Smeaton LM, Kumarasamy N, La Rosa A, Taejareonkul S, Safren SA, Flanigan TP, Hakim JG, Hughes MD; ACTG A5175/PEARLS Study Team.

HIV Clin Trials. 2016;17(5):173-180. Epub 2016 Jul 29.

9.

Engaging African and Caribbean Immigrants in HIV Testing and Care in a Large US City: Lessons Learned from the African Diaspora Health Initiative.

Kwakwa HA, Wahome R, Goines DS, Jabateh V, Green A, Bessias S, Flanigan TP.

J Immigr Minor Health. 2017 Aug;19(4):818-824. doi: 10.1007/s10903-016-0431-1.

PMID:
27198156
10.

Attitudes Toward HIV Pre-Exposure Prophylaxis in a United States Urban Clinic Population.

Kwakwa HA, Bessias S, Sturgis D, Mvula N, Wahome R, Coyle C, Flanigan TP.

AIDS Behav. 2016 Jul;20(7):1443-50. doi: 10.1007/s10461-016-1407-9.

PMID:
27115399
11.

Characterizing the Burden of Hepatitis C Infection Among Entrants to Pennsylvania State Prisons, 2004 to 2012.

Mahowald MK, Larney S, Zaller ND, Scharff N, Taylor LE, Beckwith CG, Noska A, Rich JD, Flanigan TP.

J Correct Health Care. 2016 Jan;22(1):41-5. doi: 10.1177/1078345815618384.

12.

Renal Function Recovery and HIV Viral Suppression Following Tenofovir Discontinuation for Renal Impairment.

Romo FT, Aziz M, Livak B, Huesgen E, Colton B, Flanigan TP, Max B, Kessler H.

J AIDS Clin Res. 2014 Nov;5(11). pii: 379.

13.

Outpatient parenteral antibiotic therapy in an academic practice in Rhode Island.

Touzard Romo F, Resnick B, Perez-Cioe M, Flanigan TP, Kojic EM, Beckwith CG.

R I Med J (2013). 2014 Jan 5;98(1):38-42.

14.

Tick-borne illness in Rhode Island - how big a problem is it?

Reece R, Chow EJ, Rana A, Kojic EM, Flanigan TP.

R I Med J (2013). 2014 Jan 5;98(1):35-7.

PMID:
25562059
15.

Addressing the increasing burden of sexually transmitted infections in Rhode Island.

Chan PA, Maher J, Poole D, Alexander-Scott N, Ducharme RB, Yates G, Benben S, Nunn A, Comella J, Bandy U, Montague BT, Kojic E, Chapin K, Flanigan TP.

R I Med J (2013). 2014 Jan 5;98(1):31-4.

16.

Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175).

Touzard Romo F, Smeaton LM, Campbell TB, Riviere C, Mngqibisa R, Nyirenda M, Supparatpinyo K, Kumarasamy N, Hakim JG, Flanigan TP.

HIV Clin Trials. 2014 Nov-Dec;15(6):246-60. doi: 10.1310/hct1506-246.

17.

Epidemiology of hepatitis C virus in Pennsylvania state prisons, 2004-2012: limitations of 1945-1965 birth cohort screening in correctional settings.

Larney S, Mahowald MK, Scharff N, Flanigan TP, Beckwith CG, Zaller ND.

Am J Public Health. 2014 Jun;104(6):e69-74. doi: 10.2105/AJPH.2014.301943. Epub 2014 Apr 17.

18.

Editorial commentary: Hepatitis C virus testing and drug use in north america; is there more than meets the eye?

Beckwith CG, Larney S, Flanigan TP.

Clin Infect Dis. 2014 Mar;58(6):762-4. doi: 10.1093/cid/cit941. Epub 2013 Dec 20. No abstract available.

19.

Jails: the new frontier. HIV testing, treatment, and linkage to care after release.

Flanigan TP.

AIDS Behav. 2013 Oct;17 Suppl 2:S83-5. doi: 10.1007/s10461-013-0552-7. No abstract available.

20.

Clinical impact and cost-effectiveness of expanded voluntary HIV testing in India.

Venkatesh KK, Becker JE, Kumarasamy N, Nakamura YM, Mayer KH, Losina E, Swaminathan S, Flanigan TP, Walensky RP, Freedberg KA.

PLoS One. 2013 May 31;8(5):e64604. doi: 10.1371/journal.pone.0064604. Print 2013.

21.

Contribution of substance use disorders on HIV treatment outcomes and antiretroviral medication adherence among HIV-infected persons entering jail.

Chitsaz E, Meyer JP, Krishnan A, Springer SA, Marcus R, Zaller N, Jordan AO, Lincoln T, Flanigan TP, Porterfield J, Altice FL.

AIDS Behav. 2013 Oct;17 Suppl 2:S118-27. doi: 10.1007/s10461-013-0506-0.

22.

HIV testing practices among New England college health centers.

Patel N, Rana A, Thomas A, Barnhart JC, Flanigan TP, van den Berg JJ, Chan PA.

AIDS Res Ther. 2013 Mar 18;10(1):8. doi: 10.1186/1742-6405-10-8.

23.

HIV among persons incarcerated in the USA: a review of evolving concepts in testing, treatment, and linkage to community care.

Westergaard RP, Spaulding AC, Flanigan TP.

Curr Opin Infect Dis. 2013 Feb;26(1):10-6. doi: 10.1097/QCO.0b013e32835c1dd0. Review.

24.

HIV-positive and in jail: race, risk factors, and prior access to care.

Stein MS, Spaulding AC, Cunningham M, Messina LC, Kim BI, Chung KW, Draine J, Jordan AO, Harrison A, Avery AK, Flanigan TP.

AIDS Behav. 2013 Oct;17 Suppl 2:S108-17. doi: 10.1007/s10461-012-0340-9.

PMID:
23086426
25.

Planning for success predicts virus suppressed: results of a non-controlled, observational study of factors associated with viral suppression among HIV-positive persons following jail release.

Spaulding AC, Messina LC, Kim BI, Chung KW, Lincoln T, Teixeira P, Avery AK, Cunningham M, Stein MS, Ahuja D, Flanigan TP.

AIDS Behav. 2013 Oct;17 Suppl 2:S203-11. doi: 10.1007/s10461-012-0341-8.

PMID:
23076719
26.

Risk factors for non-communicable diseases in prison populations.

Kuester LB, Flanigan TP, Clarke JG, Fletcher A.

Lancet. 2012 Oct 6;380(9849):1226-7; author reply 1227-8. doi: 10.1016/S0140-6736(12)61708-5. No abstract available.

PMID:
23040852
27.

Clinical outcomes among HIV/tuberculosis-coinfected patients developing immune reconstitution inflammatory syndrome after HAART initiation in South India.

Kumarasamy N, Venkatesh KK, Vignesh R, Devaleenal B, Poongulali S, Yepthomi T, Flanigan TP, Benson C, Mayer KH.

J Int Assoc Provid AIDS Care. 2013 Jan-Feb;12(1):28-31. doi: 10.1177/1545109712457711. Epub 2012 Sep 24.

28.

Spectrum of malignancies among HIV-infected patients in South India.

Venkatesh KK, Saghayam S, Devaleenal B, Poongulali S, Flanigan TP, Mayer KH, Kumarasamy N.

Indian J Cancer. 2012 Jan-Mar;49(1):176-80. doi: 10.4103/0019-509X.98947.

29.

Short communication: new HIV infections at Southern New England academic institutions: implications for prevention.

Chan PA, Kazi S, Rana A, Blazar I, Dejong CC, Mayer KH, Huard TK, Carleton K, Gillani F, Alexander N, Parillo Z, Flanigan TP, Kantor R.

AIDS Res Hum Retroviruses. 2013 Jan;29(1):25-9. doi: 10.1089/AID.2012.0130. Epub 2012 Jul 25.

30.

Buprenorphine for human immunodeficiency virus/hepatitis C virus-coinfected patients: does it serve as a bridge to hepatitis C virus therapy?

Taylor LE, Maynard MA, Friedmann PD, Macleod CJ, Rich JD, Flanigan TP, Sylvestre DL.

J Addict Med. 2012 Sep;6(3):179-85. doi: 10.1097/ADM.0b013e318257377f.

31.

Adherence to HIV treatment and care among previously homeless jail detainees.

Chen NE, Meyer JP, Avery AK, Draine J, Flanigan TP, Lincoln T, Spaulding AC, Springer SA, Altice FL.

AIDS Behav. 2013 Oct;17(8):2654-66. doi: 10.1007/s10461-011-0080-2.

32.

Is expanded HIV treatment preventing new infections? Impact of antiretroviral therapy on sexual risk behaviors in the developing world.

Venkatesh KK, Flanigan TP, Mayer KH.

AIDS. 2011 Oct 23;25(16):1939-49. doi: 10.1097/QAD.0b013e32834b4ced. Review.

PMID:
21811137
33.

HIV Suppression among Patients on Treatment in Vietnam: A Review of HIV Viral Load Testing in a Public Urban Clinic in Ho Chi Minh City.

Trinh TT, Montague BT, Flanigan TP, Gerard HM.

AIDS Res Treat. 2011;2011:230953. doi: 10.1155/2011/230953. Epub 2011 Feb 7.

34.

The intertwined epidemics of HIV infection, incarceration, and substance abuse: a call to action.

Flanigan TP, Beckwith CG.

J Infect Dis. 2011 May 1;203(9):1201-3. doi: 10.1093/infdis/jir034. No abstract available.

PMID:
21459812
35.

Testing for HIV, sexually transmitted infections, and viral hepatitis in jails: still a missed opportunity for public health and HIV prevention.

Flanigan TP, Zaller N, Beckwith CG, Bazerman LB, Rana A, Gardner A, Wohl DA, Altice FL.

J Acquir Immune Defic Syndr. 2010 Dec;55 Suppl 2:S78-83. doi: 10.1097/QAI.0b013e3181fbc94f.

PMID:
21406992
36.

Highly active antiretroviral therapy and employment status in accra, ghana.

Howley I, Lartey M, Machan JT, Talbot EA, Obo-Akwa A, Flanigan TP, Kwara A.

Ghana Med J. 2010 Dec;44(4):144-9.

37.

Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.

Korthuis PT, Fiellin DA, Fu R, Lum PJ, Altice FL, Sohler N, Tozzi MJ, Asch SM, Botsko M, Fishl M, Flanigan TP, Boverman J, McCarty D; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S83-90. doi: 10.1097/QAI.0b013e31820bc9a5.

38.

Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative.

Weiss L, Netherland J, Egan JE, Flanigan TP, Fiellin DA, Finkelstein R, Altice FL; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S68-75. doi: 10.1097/QAI.0b013e31820a8226.

PMID:
21317597
39.

HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.

Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, Cunningham CO, Sullivan LE, Vergara-Rodriguez P, Fiellin DA, Cajina A, Botsko M, Nandi V, Gourevitch MN, Finkelstein R; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S22-32. doi: 10.1097/QAI.0b013e318209751e.

40.

Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care.

Chaudhry AA, Botsko M, Weiss L, Egan JE, Mitty J, Estrada B, Lucas GM, Woodson T, Flanigan TP, Fiellin DA; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S14-21. doi: 10.1097/QAI.0b013e318209d3b9.

PMID:
21317589
41.

Safety, Tolerability, and Efficacy of Second-Line Generic Protease Inhibitor Containing HAART after First-Line Failure among South Indian HIV-Infected Patients.

Kumarasamy N, Venkatesh KK, Devaleenal B, Poongulali S, Yepthomi T, Solomon S, Flanigan TP, Mayer KH.

J Int Assoc Physicians AIDS Care (Chic). 2011 Mar-Apr;10(2):71-5. doi: 10.1177/1545109710382780. Epub 2011 Jan 24.

42.

Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen.

Lartey M, Sagoe KW, Yang H, Kenu E, Xexemeku F, Oliver-Commey J, Boima V, Seshie M, Sagoe A, Mingle JA, Flanigan TP, Wu H, Kwara A.

Clin Infect Dis. 2011 Feb 15;52(4):547-50. doi: 10.1093/cid/ciq196. Epub 2011 Jan 20.

43.

Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India.

Uhler LM, Kumarasamy N, Mayer KH, Saxena A, Losina E, Muniyandi M, Stoler AW, Lu Z, Walensky RP, Flanigan TP, Bender MA, Freedberg KA, Swaminathan S; CEPAC International investigators.

PLoS One. 2010 Sep 16;5(9). pii: e12747. doi: 10.1371/journal.pone.0012747.

44.

Follow-up care among HIV-infected pregnant women in Mississippi.

Rana AI, Gillani FS, Flanigan TP, Nash BT, Beckwith CG.

J Womens Health (Larchmt). 2010 Oct;19(10):1863-7. doi: 10.1089/jwh.2009.1880.

45.

Lessons learned from family-centred models of treatment for children living with HIV: current approaches and future directions.

Leeper SC, Montague BT, Friedman JF, Flanigan TP.

J Int AIDS Soc. 2010 Jun 23;13 Suppl 2:S3. doi: 10.1186/1758-2652-13-S2-S3. Review.

46.

HIV risk behavior before and after HIV counseling and testing in jail: a pilot study.

Beckwith CG, Liu T, Bazerman LB, DeLong AK, Desjardins SF, Poshkus MM, Flanigan TP.

J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):485-90. doi: 10.1097/QAI.0b013e3181c997b1.

47.

HIV and infectious disease care in jails and prisons: breaking down the walls with the help of academic medicine.

Flanigan TP, Zaller N, Taylor L, Beckwith C, Kuester L, Rich J, Carpenter CC.

Trans Am Clin Climatol Assoc. 2009;120:73-83.

48.

HIV among marginalized populations in Rhode Island.

Wakeman SE, Zaller ND, Flanigan TP, Pinkston M, Montague BT, Rich JD.

Med Health R I. 2009 Jul;92(7):244-6. No abstract available.

49.

Changes in demographics and risk factors among persons living with HIV in an academic medical center from 2003-2007.

Gillani FS, Zaller ND, Zeller K, Rich JD, Cu-Uvin S, Flanigan TP, Carpenter CC.

Med Health R I. 2009 Jul;92(7):237-40. No abstract available.

50.

Small reservoirs: jail screening for gonorrhea and Chlamydia in low prevalence areas.

Spaulding AC, Clarke JG, Jongco AM, Flanigan TP.

J Correct Health Care. 2009 Jan;15(1):28-34; quiz 80-1. doi: 10.1177/1078345808326619.

PMID:
19477809

Supplemental Content

Loading ...
Support Center